Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

20121,110 citationsJournal Articlebronze Open Access

Authors

Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 31, Issue 1, pp. 88-94

Field-Weighted Citation Impact: 58.50